Eculizumab is an antibody that binds to complement C5, inhibiting the cleavage of C5 to C5a and C5b, and is approved for the treatment of paroxysmal nocturnal hemoglobinuria [125]. This evidence concerns the gene C5AR1 and paroxysmal nocturnal hemoglobinuria.